Month: August 2021

Pivotal study VLA1553-301 met its primary endpoint Vaccine candidate induced protective CHIKV neutralizing antibody titers in 98.5% of subjects after a single vaccination VLA1553 was well tolerated across all age groups Final trial results expected within the next six monthsSaint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was recently awarded Breakthrough Designation status by the Food and Drug Administration (FDA). The trial, involving 4,115 adults, aged 18 years and above, across 44 sites in the...

Strong cash and cash equivalents position at June 30, 2021 of CHF18.1M ($19.6M) Pivotal dipraglurant PD-LID study initiated Janssen Pharmaceuticals started Phase 2 study in epilepsy with ADX71149 Dipraglurant blepharospasm study on track to start in Q3 2021 Completed $11.5M fundraising in January 2021Geneva, Switzerland, August 5, 2021 – Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year and second quarter financial results for the periods ended June 30, 2021 and provided a corporate update. “We started two clinical studies in the last 60-days, which includes our internal dipraglurant program in dyskinesia associated with Parkinson’s disease (PD-LID)...

August 5, 2021 Record–breaking backlog, increased shareholder returns, positioning for New Energy HighlightsFinancial results in line with management expectations Record-level US$29.5 billion proforma backlog, up by c. US$8 billion Launch of EUR150 million (c. US$180 million) share repurchase program Scaling-up renewables: 200 MW floating offshore wind development 2021 Directional1 revenue guidance maintained at around US$2.6 billion 2021 Directional EBITDA guidance maintained at around US$900 millionThe 2021 Half Year Results and Interim Financial Statements are published on the Company’s website under https://www.sbmoffshore.com/investor-relations-centre/financial-information/financial-results/half-year-results/. Bruno Chabas, CEO of SBM Offshore, commented: “All our three value platforms, Ocean Infrastructure, Growing the...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 5 August 2021 Fagron reports turnover of € 276.6 million Accelerated growth at Fagron Sterile Services in Wichita – turnover target raised on acquisition of US Compounding activities Financial highlights of H1 2021Turnover decreased 0.8% to € 276.6 million (+5.9% at constant exchange rates) Gross margin decreased 140 bps to 58.4% due to temporary COVID-related impact REBITDA1 decreased 11.0% to € 56.0 million REBITDA margin decreased to 20.2% (H1 2020: 22.6%) EBIT decreased 11.9% to € 40.7 million Operating cash flow increased 15.1% to € 31.3 million Net financial debt /REBITDA ratio of 2.18 at 30 June 2021 Outlook for 2021: Further turnover growth with a REBITDA between € 118 and € 124 million Strategic and operational highlightsWichita compounding facility on...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) — Melior Resources Inc. (TSXV: “MLR”) (“Melior” or the “Company”) is pleased to announce that Ranchero Gold Corp. (“Ranchero”) has closed the second tranche of its previously announced private placement (the “Concurrent Financing”) through the offering of an additional 454,545 subscription receipts (each, a “Subscription Receipt”) at a purchase price of $0.55 per Subscription Receipt for gross proceeds of $250,000. In total, Ranchero has issued an aggregate of 9,561,613 Subscription Receipts under the Concurrent Financing for aggregate gross proceeds of $5,258,887. No finders’ fees were paid in connection with this second tranche of the Concurrent Financing. Please see the...

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, acknowledges today with great sorrow that Tadataka (Tachi) Yamada, M.D., founder and chairman of the board for Passage Bio, passed away unexpectedly on August 3, 2021. “We are deeply saddened by the sudden passing of Tachi, a visionary leader in our field and co-founder of Passage Bio,” said Bruce Goldsmith, Ph.D., president and CEO, Passage Bio. “We are forever grateful for the vision, scientific experience, and strategic influence that he shared to establish our company. He has left a lasting legacy with his generous contribution to our industry, and specifically to Passage Bio and the patients we serve. We will continue...

— Trends in SaaS and Hardware are Leading FLYHT’s Path to Recovery — — Recent Private Placement and Debt Repayment Enhance Financial Position — CALGARY, Alberta, Aug. 04, 2021 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “FLYHT”) today reported financial results for the second quarter and six months ended June 30, 2021. “While the COVID pandemic remains an issue around the globe and has continued to skew FLYHT’s financial performance, we are beginning to see signs of recovery in customer confidence and the aviation industry in general which we expect will lead to improvement in our results in the quarters ahead,” said Bill Tempany, Interim CEO. “The decline in revenue in the quarter, which significantly moderated from prior periods, was mostly attributable...

CHARLOTTE, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) — Driven Brands Holdings Inc. (“Driven Brands” or the “Company”) (NASDAQ: DRVN), today announced the pricing of the underwritten secondary public offering of 12 million shares of Driven Brands’ common stock by Driven Equity LLC and RC IV Cayman ICW Holdings LLC (together the “Selling Stockholders”), each of which is a related entity of Roark Capital Management, LLC at a price of $29.50 per share. The Selling Stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock. Driven Brands is not selling any shares of common stock in the offering and will not receive any proceeds from the offering. Following the completion of the offering and assuming no exercise of the underwriters’ option to purchase additional shares, the...